Naoki Kawai

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.

Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.

Journal: The Journal of infectious diseases

Published: April 20, 2026

Impact of booster vaccinations and prior infection on COVID-19 symptom resolution during the 2025 NB.1.8.1-dominant epidemic in Japan: A retrospective multicenter study.

Impact of booster vaccinations and prior infection on COVID-19 symptom resolution during the 2025 NB.1.8.1-dominant epidemic in Japan: A retrospective multicenter study.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: February 15, 2026

Promoting COVID-19 vaccination: Results of a 2024 Japanese survey of outpatient intention to vaccinate.

Promoting COVID-19 vaccination: Results of a 2024 Japanese survey of outpatient intention to vaccinate.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: October 08, 2025

Frequency and Duration of the Clinical Symptoms of Patients With Mild COVID-19: A Comparison With Influenza in the 2023-2024 Japanese Influenza Season, an Observational Study.

Frequency and Duration of the Clinical Symptoms of Patients With Mild COVID-19: A Comparison With Influenza in the 2023-2024 Japanese Influenza Season, an Observational Study.

Journal: Health science reports

Published: September 24, 2025

Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination.

Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: August 03, 2025

Influenza vaccine effectiveness over 17 seasons in a large Japanese cohort: Analyses by age, virus type, underlying diseases and seasons before the COVID-19 pandemic.

Influenza vaccine effectiveness over 17 seasons in a large Japanese cohort: Analyses by age, virus type, underlying diseases and seasons before the COVID-19 pandemic.

Journal: Journal of infection and public health

Published: June 17, 2025

Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period.

Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: June 02, 2025

The effectiveness of repeated vaccination for COVID-19 symptom resolution during the KP.3-dominant epidemic period in Japan: A retrospective multicenter study.

The effectiveness of repeated vaccination for COVID-19 symptom resolution during the KP.3-dominant epidemic period in Japan: A retrospective multicenter study.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: May 08, 2025

Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season.

Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: November 09, 2024

In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023-24 season: Comparison with the 2010-11 to 2022-23 seasons.

In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023-24 season: Comparison with the 2010-11 to 2022-23 seasons.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: November 07, 2024

Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season.

Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season.

Journal: Influenza and other respiratory viruses

Published: September 05, 2024

Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.

Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.

Journal: Antiviral research

Published: December 19, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026